This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Compared to Estimates, Novartis (NVS) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Q2 2023 Earnings Season Gathers Pace
by Zacks Equity Research
Q2 2023 Earnings Season Gathers Pace.
Q2 Earnings Week Brings Us Tesla, Netflix & More
by Mark Vickery
Aside from a handful of Wall Street banks and other industry leaders, Q2 numbers are out this week for the first of the FAANGs and Tesla.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why Novartis (NVS) Might Surprise This Earnings Season
by Zacks Equity Research
Novartis (NVS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Novartis (NVS) to Report Q2 Earnings: Is a Beat in Store?
by Zacks Equity Research
When Novartis (NVS) reports second-quarter 2023 results, investor focus is likely to be on updates related to Sandoz's spin-off besides the top- and bottom-line numbers.
AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%
by Zacks Equity Research
AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday.
Incyte's (INCY) Opzelura Meets Goal in Phase III Pediatric Study
by Zacks Equity Research
Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase III study in children with atopic dermatitis.
Novartis (NVS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Novartis (NVS) closed at $97.16, marking a +0.63% move from the previous day.
Cigna (CI) to Add Three Biosimilars to NPF, Enable Cost Savings
by Zacks Equity Research
Cigna (CI) plans to integrate three cost-effective biosimilars within NPF in a bid to offer varied treatment options for Americans and solidify its pharmacy business.
Ionis (IONS) Posts Encouraging Data From Amyloidosis Drug Study
by Zacks Equity Research
Ionis (IONS) reports positive 85-week phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Novartis (NVS) Entresto Patent Faces Setback, Stock Down
by Zacks Equity Research
Novartis (NVS) faces a setback in the patent litigation with respect to the blockbuster heart disease drug Entresto. Shares decline.
Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study
by Zacks Equity Research
Axsome (AXSM) doses its first patient in the late-stage, label expansion study of solriamfetol for treating attention deficit hyperactivity disorder.
Amneal (AMRX) Shares Down on CRL for Parkinson's Disease Drug
by Zacks Equity Research
Amneal (AMRX) suffers a setback as the FDA issues a complete response letter (CRL) to its new drug application (NDA) for IPX203 for treating Parkinson's disease.
AstraZeneca (AZN) Down 9% on Mixed Lung Cancer Study Results
by Zacks Equity Research
While AstraZeneca's (AZN) late-stage study evaluating an experimental lung cancer treatment showed improvement in progression free survival, it did not meet the threshold for statistical significance in overall survival.
Here's Why You Should Add Alkermes (ALKS) to Your Portfolio
by Zacks Equity Research
Alkermes (ALKS), a top-ranked stock, has a diverse portfolio of neurological therapies. Its proprietary products are witnessing incremental sales.
Novartis (NVS) to Divest Xiidra, SAF312 to Streamline Focus
by Zacks Equity Research
Novartis (NVS) signs a deal to divest Xiidra and SAF312 (libvatrep) to Bausch + Lomb for $2.5 billion.
Roche (RHHBY) Announces Positive Long-Term Data on SMA Drug
by Zacks Equity Research
Roche's (RHHBY) SMA drug Evrysdi maintains its efficacy and safety profile in children with type 1 SMA after four years of treatment.
Aurinia (AUPH) Up on Paving the Way for a Potential Buyout
by Zacks Equity Research
Aurinia (AUPH) surges as management decides to explore strategic business options, including potential sale or a merger.
Immunome (IMNM) Surges on Merger Agreement With Morphimmune
by Zacks Equity Research
Immunome's (IMNM) shares rise following its announcement to merge with Morphimmune. The synergy will help strengthen the development of oncology therapies.
Bristol Myers' (BMY) Opdivo With Chemo Gets EC Nod for NSCLC
by Zacks Equity Research
Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gains European Commission approval for neoadjuvant treatment of non-small cell lung cancer, offering new hope for reducing recurrence risk.
Sigilon (SGTX) Skyrockets 441% on Buyout Offer From Eli Lilly
by Zacks Equity Research
Eli Lilly (LLY) is set to acquire Sigilon (SGTX) for $14.92 per share, in cash, along with a contingent value right of $111.64 per share.
Esperion (ESPR) to Expand Nilemdo and Nustendi Label in Europe
by Zacks Equity Research
Esperion (ESPR) files type II(a) variation application for expanded use of Nilemdo and Nustendi in Europe to reduce cardiovascular risk.
Axsome (AXSM) Down on Public Offering of Common Stock
by Zacks Equity Research
Axsome (AXSM) is set to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines.
Sanofi (SNY) Atopic Dermatitis Drug Meets Goals in Phase II Study
by Zacks Equity Research
Sanofi's (SNY) phase II study, investigating amlitelimab for moderate-to-severe atopic dermatitis in adults, meets the primary endpoint.